Posted by Michael Wonder on 27 Sep 2022
Blue Earth Diagnostics announces FDA acceptance of new drug application for 18F-rhPSMA-7.3, a radiohybrid prostate specific membrane antigen targeted PET imaging agent for prostate cancer
27 September 2022 - Blue Earth Diagnostics today announced that the US FDA has accepted its filing for a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid prostate specific membrane antigen targeted PET imaging agent.
The submission is for the use of 18F-rhPSMA-7.3 PET for diagnostic imaging of prostate cancer.
